IHMA Completes the Globalization of its Two Laboratories with the Recent College of American Pathologists (CAP) Accreditation of IHMA Europe
Enhancing Support for Clinical Trials in Anti-Infective Drug Development and Global Surveillance Studies
SCHAUMBURG, Ill., March 06, 2018 (GLOBE NEWSWIRE) -- On 14th October 2017 IHMA Europe Sàrl, located in Monthey, Valais, Switzerland, was awarded accreditation by the College of American Pathologists (CAP). With this important development both IHMA facilities, located in the US and Europe, are now CAP accredited. These accreditations further advance IHMA's global commitment to the highest quality of central laboratory clinical microbiology services that are essential for providing timely and accurate results in support of anti-infective clinical trials and global surveillance studies on a worldwide basis.
IHMA Europe's Chief Executive Officer, Dr Stephen Hawser said, "CAP accreditation is a truly positive acknowledgement of the high quality of services IHMA Europe provides to the pharmaceutical and biotechnology industries to support antimicrobial development".
Jack Johnson, President and CEO of IHMA said, "It has been our desire to globalize the two laboratories to ensure our pharmaceutical and biotechnology clients, that all services provided by IHMA and IHMA Europe are exactly the same and meet the highest standards and quality found in our industry. The CAP accreditation provides that platform."
About IHMA, Inc. and IHMA Europe S à rl
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA's services can be customized to best align with its clients' unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.
For more information, visit the IHMA website at: www.ihma.com
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Align Technology, Inc.18.2.2019 12:01:20 | Pressemeddelelse
Align Technology Launches New iTero Element 5D Imaging System for Comprehensive Preventative and Restorative Oral Care at IDS
Jobindex A/S18.2.2019 07:30:59 | Pressemeddelelse
Jobindex rammer forventningerne for 4. kvartal 2018
Computer Task Group, Incorporated15.2.2019 15:01:55 | Pressemeddelelse
CTG Promotes Three Long-time Business Leaders in Europe
Jazwares15.2.2019 01:01:37 | Pressemeddelelse
Jazwares Announces Partnership with Kellytoy for Russ Berrie™ Worldwide
SignalFx14.2.2019 16:30:07 | Pressemeddelelse
Hot Silicon Valley Tech Firm Grows in Krakow
SNOMED International14.2.2019 15:01:40 | Pressemeddelelse
HL7 and SNOMED International Announce Agreement for Free Set of Terms for Use with International Patient Summary
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum